Baxter institutes Baxter Ventures to invest $200M in promising early-stage therapies

Baxter International Inc. (NYSE:BAX) announced today that it has established Baxter Ventures to invest up to $200 million in equity in promising early-stage companies developing therapies that complement Baxter's existing portfolio.

"Baxter's mission is to apply innovative science to develop therapies and medical technologies that save and sustain patients' lives," said Robert L. Parkinson, Jr., Chairman and Chief Executive Officer of Baxter. "As the company's internal capabilities have advanced our late-stage pipeline, we have the capacity to further accelerate the early-stage development of essential therapies."

Baxter Ventures will invest globally and focus on innovative technologies with sustainable long-term growth. The company has continued to grow its internal investments in R&D and to pursue business development initiatives, collaborations and alliances as part of its long-term growth strategy.

Baxter Ventures will report into Norbert Riedel, PhD, Baxter's Chief Scientific Officer.

"Baxter Ventures will allow us to provide companies with promising, early-stage technologies with the capital and expertise needed to drive successful innovation," said Dr. Riedel. "Through this additional investment, Baxter will expand its internal pipeline with the goal of further strengthening the company's history of innovative 'firsts' in medical therapies."

Source:

Baxter International Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 24). Baxter institutes Baxter Ventures to invest $200M in promising early-stage therapies. News-Medical. Retrieved on February 04, 2023 from https://www.news-medical.net/news/20110730/Baxter-institutes-Baxter-Ventures-to-invest-24200M-in-promising-early-stage-therapies.aspx.

  • MLA

    Baxter International Inc.. "Baxter institutes Baxter Ventures to invest $200M in promising early-stage therapies". News-Medical. 04 February 2023. <https://www.news-medical.net/news/20110730/Baxter-institutes-Baxter-Ventures-to-invest-24200M-in-promising-early-stage-therapies.aspx>.

  • Chicago

    Baxter International Inc.. "Baxter institutes Baxter Ventures to invest $200M in promising early-stage therapies". News-Medical. https://www.news-medical.net/news/20110730/Baxter-institutes-Baxter-Ventures-to-invest-24200M-in-promising-early-stage-therapies.aspx. (accessed February 04, 2023).

  • Harvard

    Baxter International Inc.. 2019. Baxter institutes Baxter Ventures to invest $200M in promising early-stage therapies. News-Medical, viewed 04 February 2023, https://www.news-medical.net/news/20110730/Baxter-institutes-Baxter-Ventures-to-invest-24200M-in-promising-early-stage-therapies.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Baxter to establish new innovation and R&D center in Cambridge, MA